
















SATELLITE SYMPOSIA AND SHOWCASE THEATRE SCHEDULE

IN-PERSON AND LIVE-STREAMED 

VIRTUAL ONLY 

	SUNDAY MAY 8	MONDAY MAY 9	TUESDAY MAY 10	WEDNESDAY MAY 11
ROOM	PRE-CONGRESS	DAY 1	DAY 2	DAY 3
517c		08:00 - 09:00 Takeda From Guidelines to Practice: <u>Navigating the Current Treatment Landscape for Persons with Inhibitors</u> 	08:00 - 09:00 Novo Nordisk <u>Advancing haemophilia treatment by looking beyond clinical trials data</u> 	08:00 - 09:00 Takeda <u>On the Horizon: The Path Towards Better Joint Health for People Living with Hemophilia</u> 
517a			08:00 - 09:00 Octapharma <u>From clinical insights to patient experience: Suzanne's journey with von Willebrand disease</u> 	08:00 - 09:00 CSL Behring <u>Patient-focused care in hemophilia B: What does it mean to you?</u> 
SHOWCASE THEATRE In Exhibit Hall		10:30 - 11:00 Sanofi <u>Simple Science: Diving into the Science of Joint Bleeds</u> 	10:30 - 11:00 Sanofi <u>Behind the Lens: Our Global Responsibility</u> 	
517c		12:15 - 13:15 BioMarin <u>Gene Therapy Clinical Trial Patient Journey: A Look Into Shared Decision Making</u> 	12:15 - 13:15 Pfizer <u>Thoughtful consideration and commitment: how do we make hemophilia gene therapy a reality?</u> 	12:15 - 13:15 Takeda <u>Breaking down barriers in von Willebrand disease: Moving on from lessons learned</u> 
517a		12:15 - 13:15 Sanofi <u>Understanding The Patient Perspective in Hemophilia Management</u> 	12:15 - 13:15 Sanofi <u>Rebalancing hemophilia management: Burdens, aspirations and novel solutions</u> 	
		14:45 - 15:45 Pfizer MEET THE EXPERTS <u>Assay discrepancy when evaluating across gene therapies</u> 		12:15 - 13:15 Roche <u>Leave No One Behind: How Can We Achieve Optimal Care For All People With Hemophilia A?</u> 

The World Federation of Hemophilia does not endorse particular treatment products or manufacturers; any reference to a product name is not an endorsement by the WFH. The WFH is not a regulatory agency and cannot make recommendations relating to safety of manufacturing of specific treatment products. For recommendations of a particular product, the regulatory authority in a particular country must make these judgements based on domestic legislation and national health policies. Staff at pharmaceutical companies is not permitted by law, and by Innovative Medicines Canada, from giving information about prescription only medicines to non-healthcare professionals. Some sessions may be accessible to healthcare professionals only. According to Personal Data Protection legislation, we inform you that your personal data is part of a data file for which the World Federation of Hemophilia (WFH) is responsible. WFH processes your contact data for the purposes of keeping you informed about industry symposiums and/or any Congress-related activities.